The humanized monoclonal anti-VEGF antibody bevacizumab is the first VEGF-targeting drug approved for use in patients with metastatic colorectal cancer [60], metastatic breast cancer, lung cancer, renal cell carcinoma, and glioblastoma multiforme [61]. The gene discussed is VEGFA; the disease is lung cancer.